PNC-28 (20mg) is a synthetic peptide derived from a mitochondrial targeting sequence of p53, designed to investigate selective apoptotic mechanisms in malignant cell models. This peptide functions by interacting with mitochondrial membranes in transformed cell populations, making it a promising research tool for studies focused on cancer biology and targeted peptide therapeutics.
PNC-28 plays an important role in research examining apoptotic signaling pathways, p53-mediated stress responses, and differential cytotoxicity in neoplastic versus non-neoplastic cells. It has shown potential in modulating oncogenic processes in vitro, contributing to investigations of tumor suppression and cellular homeostasis.
In addition to its observed cytotoxic properties in malignant models, PNC-28 may support further research into tumor immunogenicity and immune system interactions with transformed cells. PNC-28 (20mg) offers a valuable compound for exploring experimental approaches related to oncology, apoptosis regulation, and cancer peptide research.
Alpha Biomed is not a compounding pharmacy or chemical compounding facility as defined under 503a of the federal food, drug, and cosmetic act. Alpha Biomed is not an outsourcing facility as defined under 503b of the federal food, drug, and cosmetic act.
Choosing a selection results in a full page refresh.
